Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 655 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Eczema, Skin Diseases, Skin Clear all
Completed Phase 1 Interventional

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

NCT03556592
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

NCT01737710
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Narrowband UVB Phototherapy on Systemic Inflammation in Patients With Atopic Dermatitis

NCT03083730
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Narrow band UVB treatment (NB-UVB)
Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Tofacitinib for Immune Skin Conditions in Down Syndrome

NCT04246372
View directory record Official record
Conditions
Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, Vitiligo, Psoriasis
Interventions
Tofacitinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

NCT03627767
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

NCT05398445
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

NCT00316602
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

NCT04684485
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Placebo, SCD-044_Dose 1, SCD-044_Dose 2, SCD-044_Dose 3
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Phoenix, Arizona • Yuma, Arizona • Encino, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

NCT06238817
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fremont, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 10, 2026, 6:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Histamine Pharmacogenetics in Children With Atopic Dermatitis

NCT00277433
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Buccal Swab
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Months to 5 Years
Enrollment
751 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
7
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03989349
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Placebo, Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

NCT06945458
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KT-621
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
12
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

NCT00919763
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
14
States / cities
Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Secukinumab for Treatment of Atopic Dermatitis

NCT02594098
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 10, 2026, 6:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema

NCT07783425
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tilrekimig, Dupilumab, Placebo for Tilrekimig, Placebo for Dupilumab
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Phoenix, Arizona • Huntington Beach, California • Northridge, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 6:14 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT04990440
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Bermekimab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05601882
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 64 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
58
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

NCT02357940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Experimental Product
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
6 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
St. Petersburg, Florida • Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

NCT01259323
View directory record Official record
Conditions
Dermatitis
Interventions
REGN668
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Los Angeles, California • Riverside, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 1Phase 2 Interventional

Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

NCT00125333
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
NF-kappaB Decoy
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
9
States / cities
Miami, Florida • Fridley, Minnesota • New York, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 10, 2026, 6:14 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Thera-Clean® Microbubbles System in Patients With Skin Diseases

NCT07050810
View directory record Official record
Conditions
Epidermolysis Bullosa, Ichthyosis, Atopic Dermatitis, Psoriasis
Interventions
TheraClean
Device
Lead sponsor
Northwestern University
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 10, 2026, 6:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Risk of Asthma in Infants With Atopic Dermatitis

NCT00459576
View directory record Official record
Conditions
Asthma, Eczema, Dermatitis, Atopic
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
2 Months to 7 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 10, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients

NCT04633616
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis, Acne
Interventions
Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 10, 2026, 6:14 PM EDT